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The clinical effects applied in calculations are summarized in Table 2 . Change of HbA1c, BMI and SBP parameters is assumed to take place in the first cycle, BMI is conservatively assumed to return to the baseline level after 5 years (at the moment of treatment switch). No additional efficacy in terms of other clinical endpoints associated with switch of treatment was assumed, excepting hypoglycemic event rates were modified.
Costs and utilities
Costs of AHAs and complications were calculated from public payer perspective based on NHF and MoH data. Complications in the CORE model include cardiovascular, renal, retinopathies and other vision problems, neuropathies, hypoglycemia, diabetic foot ulcers and amputations ( Table 3) .
Utilities of health states were established based on systematic review of published literature ( Table 3 ) [16] . The decrease of utility associated with BMI above 25 kg/m 2 was conservatively assumed at level of -0.0061 per unit BMI above 25.
RESULTS

CANA 100 + MET + SU vs NPH + MET +SU
The estimated difference in QALYs between CANA 100 + MET + SU and NPH + MET + SU is equal to 0.084 QALYs. The difference in costs is equal to 378 PLN. Incremental cost-utility ratio is equal to 4,477 PLN/QALY. The detailed results are presented in Table 4 .
One-way sensitivity analyses showed the greatest impact of HbA1c level on final results, however, extreme values of this parameter still suggest that canagliflozin is cost-effective versus NPH insulin (Figure 2) .
Modeling indicates that treatment with CANA 100 versus NPH insulin is highly costeffective, as the ICUR level is far below cost-effectiveness threshold in Poland. The scatterplot that depicts the incremental costs and QALYs from each of the 1000 cohorts is presented in Figure 1 .
CANA 300 + MET + SU vs NPH + MET + SU
The estimated difference in QALYs between CANA 300 + MET + SU and NPH + MET + SU is equal to 0.106 QALYs. The difference in costs is equal to 7,299 PLN. Incremental cost-utility ratio is equal to 69,081 PLN/QALY. The detailed results are presented in Table 5 .
Modeling indicates that treatment with CANA 300 versus NPH insulin is costeffective as the ICUR is below defined Polish cost-effectiveness threshold. The scatterplot that depicts the incremental costs and QALYs from each of the 1000 cohorts is presented on Figure 3 . The majority of the points lie in the northern quadrants indicating a positive difference in QALYs.
One-way sensitivity analyses showed the greatest impact of BMI on final results. Only in the extreme case of using a value for BMI or HbA1c set to the left end of 95% credibility interval resulted in ICURs higher than the threshold. Other scenarios confirm cost-effectiveness of canagliflozin (Figure 4 ).
CONCLUSIONS
Favorable clinical outcomes for canagliflozin (specifically weight loss and lower hypoglycemic events rates) translate into health benefit gains and into costeffectiveness of CANA 100 and CANA 300 vs NPH in the long-term. These analyses suggests that treatment algorithms with the use of CANA 100 and CANA 300 in comparison to NPH insulin as an add-on in patients needing additional HbA1c control with background MET plus SU therapy will result in a more efficient allocation of resources in the Polish setting. For both comparisons base-case ICURs are below the cost-effectiveness threshold in Poland. 
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METHODS
Scope of the analysis and its methodology is based on Polish guidelines on health technology assessment (HTA).
The IMS CORE Diabetes Model (www.core-diabetes.com) was used to evaluate cost-effectiveness of canagliflozin. The CORE Model is a validated [11] and widely used tool allowing to simulate diabetes progression in lifetime horizon. It implements Markov model using series of interconnected sub-models representing diabetes complications. The model offers the possibility to implement country-specific and intervention-specific data. Polish data on costs of drugs and treatment for T2DM related complications' and all cause (i.e. non-T2DM-related) mortality rates were applied into the model. Clinical effectiveness data were sourced from randomized clinical trials (RCTs) comparing canagliflozin or NPH insulin to other interventions. The effectiveness of interventions was measured by change in HbA1c, BMI, systolic blood pressure (SBP), lipids levels and hypoglycemic event rates. Utilities data were obtained from a systematic review of published literature on quality of life of patients with diabetes and its complications, which was conducted according to Polish HTA guidelines.. Costs of drugs and treatment of diabetes complications were calculated using data from Polish National Health Fund (NHF) and Ministry of Health (MoH).
A lifetime horizon was adopted, so that the impact of long-term complications of T2DM could be assessed. Outcomes were discounted according to Polish HTA guidelines (costs were discounted at 5% and health effects with 3.5%).
It was assumed that patients are treated with canagliflozin or NPH insulin for 5 years and later switch to premixed insulin + MET + SU therapy, which is then continued lifetime. Treatment with premixed insulin in the following line is in agreement with Polish guidelines of T2DM treatment.
The main outcomes of the analysis were costs and QALYs (quality-adjusted life years). Costs were reported in Polish zloty (PLN, 1 EUR = 4.10 PLN). Based on the cost and QALY results, incremental cost-utility ratio (ICUR) was calculated and compared to the cost-effectiveness threshold, which is 111,381 PLN/QALY in Poland (2014).
In order to measure uncertainty of obtained results, probabilistic sensitivity analysis (PSA) and series of one-way sensitivity analyses were conducted.
DATA Baseline characteristics
Baseline characteristic were sourced from RCTs for canagliflozin [9, 10] and Polish observational studies [12] [13] [14] . The values used in the analysis are presented in Table 1 .
OBJECTIVE
The objective of the analysis was to assess cost-effectiveness of canagliflozin (Invokana®) as add-on to metformin (MET) and sulfonylurea (SU) compared to NPH insulin in treatment of T2DM in adult patients. The analysis was conducted in Polish setting from a public payer perspective.
BACKGROUND
■ Type 2 diabetes mellitus (T2DM) generally occurs in people older than 40 years; the incidence increases with age, with more than 10% of people over 65 years having T2DM. In recent years, T2DM more often arises at a younger age due to an increasingly obese society, poor childhood dietary habits, and sedentary lifestyles [1] [2] [3] .
■ T2DM is a major public health problem and affects 10 million people in Europe (4% of the total population). Based on World Health Organization (WHO) estimates, by 2030, the number of people with diabetes could be over 350 million throughout the world [4] . Estimated prevalence of T2DM in Poland is about 6.5% [5] .
■ Canagliflozin (CANA) is a novel, oral antihyperglycaemic agent (AHA) with sodium glucose co-transporter 2 (SGLT2) inhibition developed for the treatment of adults with T2DM [11, 12] ; CANA was approved for use in the European Union in November 2013.
○ By inhibiting SGLT2, CANA reduces renal glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose [6] [7] [8] ; this independent of pancreatic ß cell function mechanism of action makes it complementary to other AHAs, including insulin.
■ In Phase 3 studies, CANA:
○ Provided improved glycaemic control and body weight and blood pressure reductions.
○ Was generally well tolerated, with an increased incidence of adverse events (AEs) related to the mechanism of action (eg, genital mycotic infections, urinary tract infections, AEs related to osmotic diuresis), but a low inherent risk of hypoglycaemia, such that discontinuation due to AEs was low and generally similar in the CANA and non-CANA patients [9, 10] . -2,500 -2,000 -1,500 -1,000 -0,500 0,000 0,500 1,000 1,500 2,000 2,500
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